Investigational drug · Phase 3
PTM F
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pre-Exposure Prophylaxis of HIV Infection.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "PTM F"
First trial start
2021
Jun 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PTM F", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pre-Exposure Prophylaxis of HIV Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "PTM F" as an intervention, largest first.
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04925752 · 3,292 participants · Start Jun 28, 2021 · Primary completion Aug 21, 2024
Drug: Oral Lenacapavir (LEN); F/TDF and 5 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 93 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630286 · 609 participants · Start Oct 9, 2024 · Primary completion Apr 17, 2026
Drug: ISL/LEN; B/F/TAF and 2 more · For: HIV-1-infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 106 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06333808 · 577 participants · Start Mar 25, 2024 · Primary completion Oct 27, 2025
Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC; Lenacapavir and 4 more · For: HIV-1-infection
Sites: Phoenix, Arizona; Berkeley, California; Beverly Hills, California · 104 sites in all
- Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT03547908 · 244 participants · Start May 30, 2018 · Primary completion Feb 25, 2022
Drug: B/F/TAF; Placebo to match DTG and 4 more · For: HIV-1/HBV Co-Infection
Sites: Ft. Pierce, Florida; West Palm Beach, Florida; Berkley, Michigan · 69 sites in all
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT06613685 · 73 participants · Start Oct 21, 2024 · Primary completion Mar 16, 2026
Drug: lepetegravir; lenacapavir pacfosacil and 4 more · For: HIV-1-infection
Sites: Birmingham, Alabama; Torrance, California; West Hollywood, California · 58 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pre-Exposure Prophylaxis of HIV Infection
- PTM LENPhase 32 trials
Gilead Sciences · Pre-Exposure Prophylaxis of HIV Infection
- Sub-cutaneous LenacapavirPhase 31 trial
Gilead Sciences · Pre-Exposure Prophylaxis of HIV Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.